June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Factors Associated with Enlargement of Choroidal Microvascular Dropout in Glaucoma
Author Affiliations & Notes
  • Eleonora Micheletti
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Sasan Moghimi
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Takashi Nishida
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Nevin W. El-Nimri
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Golnoush Mamoudinezhad
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Alireza Kamalipour
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Vahid Mohammadzadeh
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Linda Zangwill
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Robert N Weinreb
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Eleonora Micheletti None; Sasan Moghimi None; Takashi Nishida None; Nevin El-Nimri None; Golnoush Mamoudinezhad None; Alireza Kamalipour None; Vahid Mohammadzadeh None; Linda Zangwill Abbvie inc. Digital Diagnostics, Code C (Consultant/Contractor), National Eye Institute, Carl Zeiss Meditec Inc., Heidelberg Engineering GMBH, Optovue Inc., Topcon Medical System Inc., Code F (Financial Support), Zeiss Meditec, Code P (Patent); Robert Weinreb Abbvie, Aerie Pharmaceuticals, Allergan, Equinox, Eyenovia, Nicox, Topcon, Code C (Consultant/Contractor), Heidelberg Engineering, Carl Zeiss Meditec, Konan Medical, Optovue, Centervue, Bausch&Lomb, Topcon, Code F (Financial Support), Toromedes, Carl Zeiss Meditec, Code P (Patent)
  • Footnotes
    Support  National Eye Institute R01EY029058, R01EY11008, R01EY19869, R01EY027510, R01EY026574, EY018926 P30EY022589, Unrestricted grants from Research to Prevent Blindness (New York, NY), National Eye Institute; Research to Prevent Blindness, Tobacco-Related Disease Research Program T31IP1511
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3332 – F0141. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eleonora Micheletti, Sasan Moghimi, Takashi Nishida, Nevin W. El-Nimri, Golnoush Mamoudinezhad, Alireza Kamalipour, Vahid Mohammadzadeh, Linda Zangwill, Robert N Weinreb; Factors Associated with Enlargement of Choroidal Microvascular Dropout in Glaucoma. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3332 – F0141.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the factors associated with choroidal microvasculature dropout (MvD) enlargement detected by optical coherence tomography angiography (OCT-A) in glaucoma eyes.

Methods : Ninety-one eyes of 68 primary open angle glaucoma (POAG) patients were enrolled. Only eyes with 4 good quality OCT-A and OCT scans of the optic nerve head with 2 years follow-up were included. Area of MvD were analyzed on en-face images at each visit (see Figure). Univariable and multivariable mixed effects models were constructed to identify the factors contributing to MvD area over time.

Results : Peripapillary MvD was detected in 53 (58.2%) eyes at baseline and in an additional 17 (18.7%) eyes during follow-up, whereas MvD was not detected in 21 (23.1 %) eyes during the entire follow-up period. In eyes with MVD at baseline, mean baseline MVD area was 0.15 (0.09, 0.22) mm2. In eyes with MvD at baseline, mean (95% CI) of rate enlargement of MVD area was 0.05 (0.04, 0.06) mm2/year. In the univariable model, worse baseline VF MD (coefficient ß =0.27, 95%CI: 0.10, 0.44, P=0.002), greater intraocular pressure (IOP) fluctuations (ß=0.86, 95% CI: 0.24, 1.48, P=0.007), higher peak IOP (ß=0.17, 95% CI: -0.01, 0.35, P=0.067) and greater number of IOP lowering medications (ß =1.36, 95% CI: 0.67, 2.05, P<0.001) were associated with faster MvD area enlargement (Table 1). In the multivariable model, worse baseline VF MD, greater IOP fluctuations, higher peak IOP and greater number of IOP lowering medications remained significantly associated with faster MvD area enlargement (Table 1). No associations were found between mean IOP during follow-up and MvD changes over time. In the 17 eyes that developed MvD during follow-up, long-term IOP fluctuation [95% CI], defined as the standard deviation of IOP measurements during follow-up, was significantly greater (3.5 [2.3, 4.7] mmHg) in eyes with MvD compared to eyes that did not develop MvD (1.9 [1.5, 2.3] mmHg, P=0.012).

Conclusions : IOP fluctuation was associated with MvD enlargement and development. Other factors, including peak IOP, worse baseline VF MD and number of glaucoma medications were significantly associated with MvD area enlargement in glaucomatous eyes. The identification of factors associated with MvD enlargement may improve our understanding of the role of choroidal microvasculature in glaucoma.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Choroidal microvasculature dropout (MvD) area, manually outlined using ImageJ software.

Choroidal microvasculature dropout (MvD) area, manually outlined using ImageJ software.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×